Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells

Abstract

While targeted therapy brought a new era in the treatment of BRAF mutant melanoma, therapeutic options for non-BRAF mutant cases are still limited. In order to explore the antitumor activity of prenylation inhibition we investigated the response to zoledronic acid treatment in thirteen human melanoma cell lines with known BRAF, NRAS and PTEN mutational status. Effect of zoledronic acid on proliferation, clonogenic potential, apoptosis and migration of melanoma cells as well as the activation of downstream elements of the RAS/RAF pathway were investigated in vitro with SRB, TUNEL and PARP cleavage assays and videomicroscopy and immunoblot measurements, respectively. Subcutaneous and spleen-to-liver colonization xenograft mouse models were used to evaluate the influence of zoledronic acid treatment on primary and disseminated tumor growth of melanoma cells in vivo. Zoledronic acid more efficiently decreased short-term in vitro viability in NRAS mutant cells when compared to BRAF mutant and BRAF/NRAS wild-type cells. In line with this finding, following treatment decreased activation of ribosomal protein S6 was found in NRAS mutant cells. Zoledronic acid demonstrated no significant synergism in cell viability inhibition or apoptosis induction with cisplatin or DTIC treatment in vitro. Importantly, zoledronic acid could inhibit clonogenic growth in the majority of melanoma cell lines except in the three BRAF mutant but PTEN wild-type melanoma lines. A similar pattern was observed in apoptosis induction experiments. In vivo zoledronic acid did not inhibit the subcutaneous growth or spleen-to-liver colonization of melanoma cells. Altogether our data demonstrates that prenylation inhibition may be a novel therapeutic approach in NRAS mutant melanoma. Nevertheless, we also demonstrated that therapeutic sensitivity might be influenced by the PTEN status of BRAF mutant melanoma cells. However, further investigations are needed to identify drugs that have appropriate pharmacological properties to efficiently target prenylation in melanoma cells.

Complications of bone metastases from malignant melanoma

“…There is in vitro and in vivo evidence that ZA induces death of melanoma cells [29] . Certainly, there are no strong clinical data to support this notion in the clinical setting.…”

Physiologic Activity of Bisphosphonates – Recent Advances

“…Thus, they should be considered as possible anti-cancer agents. This reasoning is supported by the ability of these compounds to suppress proliferation of cancer cells of prostate, [119] breast, [120,121] melanoma, [122] ovarian [123] and colorectal cancers, [124] as well as glioblastoma [125] and multiple myelanoma [126]. Additionally these drugs have also been shown to kill cancers in humans independently on their action on bones.…”

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells

“…Activation status of the BRAF mutations are from Zheng et al, 2015 [ 6 ]. Cell lines have no known additional mutations in PI3K or PTEN [ 23 – 27 ].…”